Disclosure under Regulation 30 of SEBI (LODR), 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech's Board of Directors met on September 2, 2025 and approved several items. First, they approved altering the company's Memorandum of Association (MOA) to align it with the Companies Act, 2013, though the main objects of the company remain unchanged — this still needs shareholder approval. Second, the 40th Annual General Meeting (AGM) has been scheduled for September 30, 2025, to be held via video conferencing. Third, the Board approved the Board's Report for the financial year ended March 31, 2025. Finally, Mr. Amit Kumar has been re-appointed as Manager of the company for a further 5-year term, from February 12, 2026 to February 11, 2031, subject to shareholder approval.
These are largely routine corporate governance and compliance items with no change in the company's main business activities. Shareholders should watch the September 30, 2025 AGM for the MOA alteration and Manager re-appointment voting. The Manager re-appointment ensures leadership continuity and is unlikely to materially affect the stock price.